Brief: FDA Approves Apellis' Empaveli (Pegcetacoplan) As The First C3g And Primary IC-Mpgn Treatment For Patients 12 And Older
29/07/2025 24:21
July 28 (Reuters) - Apellis Pharmaceuticals Inc APLS.O: FDA APPROVES APELLIS’ EMPAVELI® (PEGCETACOPLAN) AS THE FIRST C3G AND PRIMARY IC-MPGN TREATMENT FOR PATIENTS 12 AND OLDER Source text: ID:nGNX3XrWT7 Further company coverage: APLS.O ((Reuters.Briefs@thomsonreuters.com;))